Ads
related to: pfizer
Search results
Is It Too Late to Buy Pfizer Stock?
The Motley Fool via AOL· 3 hours agoAre Pfizer's (NYSE: PFE) best days behind it? If the stock's critics are to be believed, the answer is an emphatic "yes, obviously," with issues like its...
Pfizer Inc. (NYSE:PFE) Shares Sold by Public Employees Retirement System of Ohio
ETF DAILY NEWS· 8 hours agoPublic Employees Retirement System of Ohio reduced its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 1.8% during the 4th quarter, HoldingsChannel reports. The ...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 21 hours agoPfizer disclosed on May 7 that a child participating in another...
Studio Investment Management LLC Buys 2,236 Shares of Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 6 hours agoStudio Investment Management LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.1% during the 4th quarter, according to the company in its most ...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 1 day agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 1 day agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 1 day agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 2 days agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 18 hours agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer: An Oversold Pharma Stock in Recovery
GuruFocus.com via Yahoo Finance· 2 days agoSome say the art of investing is the ability of catching falling knives. Pfizer Inc. (NYSE:PFE) shares have sold off in 2023 and represent an attractive...
